title: [The efficacy and safety of indisetron hydrochloride for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer].
abstract: This clinical trial was designed to evaluate the efficacy and safety of indisetron hydrochloride an oral 5-HT3 receptor antagonist, for the management of nausea/vomiting caused by chemotherapy for gynecologic cancer with paclitaxel/ carboplatin or docetaxel/carboplatin. Indisetron hydrochloride(8 mg)was administered orally to 46 gynecologic cancer patients at 0.5 hours before administration of the above chemotherapy agents. Number of patients who showed nausea or vomiting for 24 hours was counted. The complete vomiting inhibition rate at 24 hours after chemotherapy was 89.1%(41/46), and nausea inhibition rate was 71.7%(33/46). No serious adverse events were observed. These findings indicate that prophylactic administration of indisetron hydrochloride is safe and useful for inhibition of nausea/vomiting caused by cancer chemotherapy.
authors.affiliation: Dept. of Obstetrics and Gynecology, Kurume University School of Medicine.
authors.forename: Kimio
authors.initials: K
authors.lastname: Ushijima
authors.forename: Norio
authors.initials: N
authors.lastname: Wake
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kobayashi
authors.forename: Toru
authors.initials: T
authors.lastname: Hachisuga
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Toki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Masuzaki
authors.forename: Kohei
authors.initials: K
authors.lastname: Kotera
authors.forename: Tatsuhiko
authors.initials: T
authors.lastname: Kawarabayashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Emoto
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Kamura
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D009325:Nausea / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011720:Pyrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D011720:Pyrazoles; C500220:indisetron hydrochloride